Tonix Pharma (TNXP) – Major News
-
Tonix Pharma (TNXP) Misses Q2 EPS by 215c
-
Tonix Pharma (TNXP) Tops Q4 EPS by 46c
-
Tonix Pharma (TNXP) Phase 3 RECOVERY Study of Tonmya in PTSD Halted Due to Futility
-
Tonix Pharma (TNXP) Will Stop Ph3 HONOR Study of Tonmya in PTSD Due to Inadequate Separation from Placebo on Primary Endpoint
-
Tonix Pharma (TNXP) Reports Q4 Loss of $2.08/Share
-
Tonix Pharmaceuticals (TNXP) Reports Q3 Loss of $0.29/Share
-
Tonix Pharmaceuticals (TNXP) Reports Q2 Loss of $0.50/Share
-
Tonix Pharmaceuticals (TNXP) Misses Q4 EPS by 5c
-
Tonix Pharmaceuticals (TNXP) Says TNX-201 Missed Primary Efficacy Endpoint in ETTH Phase 2
-
Tonix Pharmaceuticals (TNXP) Misses Q2 EPS by 8c
-
Tonix Pharmaceuticals (TNXP) Misses Q1 EPS by 17c
-
Tonix Pharmaceuticals (TNXP) Misses Q4 EPS by 2c
-
Tonix Pharmaceuticals (TNXP) Misses Q3 EPS by 2c
-
Tonix Pharm Hldg (TNXP) Misses Q2 EPS by 8c
-
Tonix Pharm Hldg (TNXP) Posts Q1 Loss of 59c/Share
Back to TNXP Stock Lookup